Telix Pharmaceuticals (TLPPF) Stock Forecast & Price Target

Q: What is TLPPF’s average 12-month price target, according to analysts?

Based on analyst ratings, Telix Pharmaceuticals Ltd.’s 12-month average price target is 17.61.

Q: What is TLPPF’s upside potential, based on the analysts’ average price target?

Telix Pharmaceuticals Ltd. has 70.64% upside potential, based on the analysts’ average price target.

Q: Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

Q: How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Q: Is TLPPF a Buy, Sell or Hold?

Telix Pharmaceuticals Ltd. has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

Q: What is Telix Pharmaceuticals Ltd.’s price target?

The average price target for Telix Pharmaceuticals Ltd. is 17.61. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $23.04 ,the lowest forecast is $10.86. The average price target represents 70.64% Increase from the current price of $10.32.

Q: What do analysts say about Telix Pharmaceuticals Ltd.?

Telix Pharmaceuticals Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

Q: How can I buy shares of TLPPF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Compare

143 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TLPPF Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Telix

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TLPPF Stock 12 Month Forecast

Average Price Target

$17.61

▲(70.64% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Telix Pharmaceuticals in the last 3 months. The average price target is $17.61 with a high forecast of $23.04 and a low forecast of $10.86. The average price target represents a 70.64% change from the last price of $10.32.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","12":"$12","16":"$16","20":"$20","24":"$24"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23.04162,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.862478,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.86</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,12,16,20,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.36,10.412432307692308,11.464864615384615,12.517296923076923,13.56972923076923,14.622161538461539,15.674593846153847,16.727026153846154,17.77945846153846,18.83189076923077,19.884323076923078,20.936755384615388,21.989187692307695,{"y":23.04162,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.36,9.994615384615384,10.62923076923077,11.263846153846153,11.898461538461538,12.533076923076923,13.167692307692306,13.802307692307691,14.436923076923076,15.071538461538461,15.706153846153846,16.34076923076923,16.975384615384613,{"y":17.61,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.36,9.47557523076923,9.591150461538462,9.706725692307693,9.822300923076922,9.937876153846153,10.053451384615384,10.169026615384615,10.284601846153846,10.400177076923077,10.515752307692306,10.631327538461537,10.746902769230768,{"y":10.862478,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.29,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.06,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.08,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$23.04

Average Price Target$17.61

Lowest Price Target$10.86

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Laura Sutcliffe

Citi

$22.38

Buy

116.89%

Upside

Reiterated

10/23/25

Citi Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

John Hester

Bell Potter

$15.14

Buy

46.72%

Upside

Reiterated

10/22/25

Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Steven Wheen

Jarden

$18.52→$18.47

Buy

79.00%

Upside

Reiterated

10/16/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA), Telix Pharmaceuticals (Other OTC: TLPPF) and Geron (NASDAQ: GERN)

Tara Bancroft

TD Cowen

$23.04

Buy

123.27%

Upside

Reiterated

10/15/25

Telix Pharmaceuticals: Strong Q3 Performance and Strategic Positioning Reinforce Buy Rating2:46 PM Telix Pharmaceuticals (ASX: TLX) Buy (1) ESG Q3: PSMA Report THE TD COWEN INSIGHT Telix pre-reported Q3 total revenue of $206MM, ahead of expectations as the PSMA diagnostic franchise volume grew +3%, but growth was offset by pricing pressures that appear to be stabilizing. Guidance increased $25MM at the midpoint ($800-820MM), where the low end is achievable, and Gozellix should add in 2026. Several pipeline updates expected over the next 12 months could also generate value. PSMA Pricing Pressure...

David Bailey

Morgan Stanley

$16.85→$16.72

Buy

62.03%

Upside

Reiterated

10/15/25

Morgan Stanley Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Madeleine Williams

Canaccord Genuity

$17.99→$18.04

Buy

74.85%

Upside

Reiterated

10/15/25

Canaccord Genuity Remains a Buy on Telix Pharmaceuticals (TLPPF)Canaccord Genuity raised its price target on Telix Pharmaceuticals Ltd (TLX:AU) to AUD27.41 (from AUD27.33) while maintaining a Buy rating.

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$14.88

Buy

44.17%

Upside

Reiterated

10/15/25

Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett

David Stanton

Jefferies

$17.58→$17.84

Buy

72.88%

Upside

Reiterated

10/14/25

Jefferies Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)Jefferies analyst David Stanton raised the price target on Telix Pharmaceuticals Ltd (TLX:AU) to AUD27.10 (from AUD26.70) while maintaining a Buy rating.

David Dai

UBS

$20.41

Buy

97.75%

Upside

Reiterated

10/14/25

Telix Pharmaceuticals (TLPPF) Gets a Buy from UBS

Andrew Paine

CLSA

$15.96

Buy

54.70%

Upside

Reiterated

10/03/25

CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)CLSA analyst Andrew Paine reiterated an Outperform (2) rating and AUD24.25 price target on Telix Pharmaceuticals Ltd (TLX:AU).

David Low

J.P. Morgan

$17.28→$10.86

Hold

5.26%

Upside

Downgraded

08/31/25

J.P. Morgan downgrades Telix Pharmaceuticals (TLPPF) to a Hold

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Laura Sutcliffe

Citi

$22.38

Buy

116.89%

Upside

Reiterated

10/23/25

Citi Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

John Hester

Bell Potter

$15.14

Buy

46.72%

Upside

Reiterated

10/22/25

Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Steven Wheen

Jarden

$18.52→$18.47

Buy

79.00%

Upside

Reiterated

10/16/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA), Telix Pharmaceuticals (Other OTC: TLPPF) and Geron (NASDAQ: GERN)

Tara Bancroft

TD Cowen

$23.04

Buy

123.27%

Upside

Reiterated

10/15/25

David Bailey

Morgan Stanley

$16.85→$16.72

Buy

62.03%

Upside

Reiterated

10/15/25

Morgan Stanley Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Madeleine Williams

Canaccord Genuity

$17.99→$18.04

Buy

74.85%

Upside

Reiterated

10/15/25

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

$14.88

Buy

44.17%

Upside

Reiterated

10/15/25

Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett

David Stanton

Jefferies

$17.58→$17.84

Buy

72.88%

Upside

Reiterated

10/14/25

David Dai

UBS

$20.41

Buy

97.75%

Upside

Reiterated

10/14/25

Telix Pharmaceuticals (TLPPF) Gets a Buy from UBS

Andrew Paine

CLSA

$15.96

Buy

54.70%

Upside

Reiterated

10/03/25

CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)CLSA analyst Andrew Paine reiterated an Outperform (2) rating and AUD24.25 price target on Telix Pharmaceuticals Ltd (TLX:AU).

David Low

J.P. Morgan

$17.28→$10.86

Hold

5.26%

Upside

Downgraded

08/31/25

J.P. Morgan downgrades Telix Pharmaceuticals (TLPPF) to a Hold

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Telix Pharmaceuticals

1 Month

xxx

Success Rate

11/16 ratings generated profit

Average Return

+7.23%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 68.75% of your transactions generating a profit, with an average return of +7.23% per trade.

3 Months

xxx

Success Rate

12/16 ratings generated profit

Average Return

+26.36%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +26.36% per trade.

1 Year

Steven WheenJarden

Success Rate

16/21 ratings generated profit

Average Return

+54.75%

reiterated a buy rating 15 days ago

Copying Steven Wheen's trades and holding each position for 1 Year would result in 76.19% of your transactions generating a profit, with an average return of +54.75% per trade.

2 Years

xxx

Success Rate

14/21 ratings generated profit

Average Return

+106.49%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +106.49% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TLPPF Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TLPPF has received 33 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. TLPPF average Analyst price target in the past 3 months is 17.61.

Each month's total comprises the sum of three months' worth of ratings.

TLPPF Financial Forecast

TLPPF Earnings Forecast

Next quarter’s earnings estimate for TLPPF is $0.23 with a range of $0.05 to $0.42. The previous quarter’s EPS was <$0.01. TLPPF beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year TLPPF has Preformed in-line its overall industry.

TLPPF Sales Forecast

Next quarter’s sales forecast for TLPPF is $209.42M with a range of $205.65M to $213.19M. The previous quarter’s sales results were $400.72M. TLPPF beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year TLPPF has Preformed in-line its overall industry.

TLPPF Stock Forecast FAQ

What is TLPPF’s average 12-month price target, according to analysts?

Based on analyst ratings, Telix Pharmaceuticals Ltd.’s 12-month average price target is 17.61.

What is TLPPF’s upside potential, based on the analysts’ average price target?

Telix Pharmaceuticals Ltd. has 70.64% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TLPPF a Buy, Sell or Hold?

Telix Pharmaceuticals Ltd. has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is Telix Pharmaceuticals Ltd.’s price target?

The average price target for Telix Pharmaceuticals Ltd. is 17.61. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $23.04 ,the lowest forecast is $10.86. The average price target represents 70.64% Increase from the current price of $10.32.

What do analysts say about Telix Pharmaceuticals Ltd.?

Telix Pharmaceuticals Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of TLPPF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Telix Pharmaceuticals (TLPPF) Stock Forecast & Price Target

TLPPF Analyst Ratings

TLPPF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Telix Pharmaceuticals

TLPPF Analyst Recommendation Trends

TLPPF Financial Forecast

TLPPF Earnings Forecast

TLPPF Sales Forecast

TLPPF Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts